These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Goldenberg MM Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845 [TBL] [Abstract][Full Text] [Related]
4. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs. Everts B; Währborg P; Hedner T Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820 [TBL] [Abstract][Full Text] [Related]
5. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544 [TBL] [Abstract][Full Text] [Related]
6. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Song X; Lin HP; Johnson AJ; Tseng PH; Yang YT; Kulp SK; Chen CS J Natl Cancer Inst; 2002 Apr; 94(8):585-91. PubMed ID: 11959891 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467 [TBL] [Abstract][Full Text] [Related]
9. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374 [TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111 [TBL] [Abstract][Full Text] [Related]
11. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821 [TBL] [Abstract][Full Text] [Related]
12. Celecoxib, a COX-2--specific inhibitor: the clinical data. Fort J Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):13-8. PubMed ID: 10193998 [TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Kusunoki N; Yamazaki R; Kawai S Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Davies NM; McLachlan AJ; Day RO; Williams KM Clin Pharmacokinet; 2000 Mar; 38(3):225-42. PubMed ID: 10749518 [TBL] [Abstract][Full Text] [Related]
15. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902 [TBL] [Abstract][Full Text] [Related]
16. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. Tindall E J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176 [TBL] [Abstract][Full Text] [Related]
17. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Wallace JL; McKnight W; Reuter BK; Vergnolle N Gastroenterology; 2000 Sep; 119(3):706-14. PubMed ID: 10982765 [TBL] [Abstract][Full Text] [Related]
18. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261 [TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 specificity and its clinical implications. Lefkowith JB Am J Med; 1999 May; 106(5B):43S-50S. PubMed ID: 10390127 [TBL] [Abstract][Full Text] [Related]
20. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Zhu J; Huang JW; Tseng PH; Yang YT; Fowble J; Shiau CW; Shaw YJ; Kulp SK; Chen CS Cancer Res; 2004 Jun; 64(12):4309-18. PubMed ID: 15205346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]